Johns Hopkins University School of Medicine Presentation Highlights SELDI Technology for Proteomic Analysis in Kidney Transplant
June 24 2004 - 10:00AM
PR Newswire (US)
Johns Hopkins University School of Medicine Presentation Highlights
SELDI Technology for Proteomic Analysis in Kidney Transplantation
Rejection Study Ciphergen's ProteinChip(R) System Enables Discovery
of Multiple Biomarkers and Predictive Assay for Kidney Transplant
Rejection FREMONT, Calif., June 24 /PRNewswire-FirstCall/ --
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today the recent
report of a promising study in kidney transplantation enabled by
Ciphergen's SELDI ProteinChip(R) System. The findings were enabled
by the use of proteomic pattern discovery and recognition
methodologies pioneered by Ciphergen's Biomarker Discovery
Center(R) joint venture with the Johns Hopkins School of Medicine.
This methodology was used to develop the basis of a simple urine
test that identifies impending kidney failure or rejection
following transplant surgery -- a potential alternative to kidney
biopsies for renal transplant patient monitoring. Dr. Dan Chan,
Professor of Pathology, Oncology, Urology, and Radiology at Johns
Hopkins School of Medicine, commented, "SELDI proteomics discovers
the most predictive biomarkers from a large number of marker
candidates, potentially giving it significant advantages over
conventional proteomic methods. The SELDI proteomics approach
rapidly discovers the best markers and translates them to a
SELDI-based assay using a single platform and process." On May 16th
of this year, researchers from the Johns Hopkins University School
of Medicine provided a special invited lecture to the American
Transplant Congress in Boston, Massachusetts in which they reported
finding thirteen potential protein biomarkers present in greater
concentrations in urine samples from patients who had organ
rejection following kidney transplant than were present in most
non-rejection samples. Three other potential biomarkers were found
to be lower in patients' urine with the onset of transplant
rejection. A separate analysis using a combination of biomarker
candidates in a panel correctly identified 91% of the 34 urine
samples from 32 kidney patients at various stages after
transplantation. As a potential alternative to expensive and
painful kidney biopsies, frequent non-invasive monitoring through a
urine-based, multi-biomarker panel could allow doctors to better
tailor immunosuppression drugs according to individual patient's
needs, prescribing lower doses to more stable patients or
increasing doses for patients who show early signs of rejection.
"This has the potential to change the way transplant patients are
managed," said study co-author Ernesto P. Molmenti, M.D., Ph.D.,
associate professor of surgery at Johns Hopkins. "Frequent,
noninvasive monitoring could allow doctors to more rapidly respond
to patients who show early signs of rejection." In this study,
urine samples were collected from 17 transplant recipients with
acute rejection and 15 patients with no rejection. Processed urine
samples were analyzed in triplicate by SELDI using immobilized
metal affinity (IMAC3) and hydrophobic (H4) ProteinChip Arrays.
Mass spectra generated by SELDI were subjected to bioinformatics
analysis both by ProPeak (a program developed by Dr. Zhen Zhang at
Johns Hopkins) and Ciphergen's Biomarker Patterns(TM) Software.
Initial data analysis revealed 45 peaks that showed the ability to
distinguish between rejection and non-rejection urine samples. From
these peaks of interest, 16 peaks showed promise as transplant
rejection biomarkers. Ultimately, a multiple-biomarker panel was
utilized to achieve the correct stratification of 91% of the
samples. "Unlike kidney biopsy, which can cause significant
complications in transplant patients, a urine test is risk-free,
presents no discomfort for the patients, and samples the entire
kidney accurately," stated study co-author William Clarke, Ph.D.,
assistant professor of pathology at Johns Hopkins. About Ciphergen
Ciphergen's Biosystems Division develops, manufactures and markets
a family of ProteinChip(R) Systems and services for clinical,
research, and process proteomics applications, as well as a broad
range of bioseparations media for protein purification and large
scale production. ProteinChip Systems enable protein discovery,
characterization, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a
better understanding of biological function at the protein level.
Ciphergen's Diagnostics Division is dedicated to the discovery of
protein biomarkers and panels of biomarkers and their development
into protein molecular diagnostic tests that improve patient care;
and to providing collaborative R&D services through its
Biomarker Discovery Center(R) laboratories for biomarker discovery
for new diagnostic tests as well as pharmacoproteomic services for
improved drug toxicology, efficacy and theranostic assays.
Additional information about Ciphergen can be found at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the potential advantage of
the SELDI proteomics approach, potential benefits of non-invasive
monitoring of kidney transplant patients through a urine-based,
multi-biomarker panel, the use of ProteinChip technology to
discover useful protein biomarkers that can act as novel drug
targets or disease markers, develop and commercialize clinical
diagnostics that improve patient care, the ability to provide
services that lead to improved toxicology assays and diagnostic
assays, and statements regarding our Diagnostics Division. Actual
results may differ materially from those projected in such
forward-looking statements due to various factors, including the
ProteinChip technology's ability to validate and/or develop protein
biomarkers as novel drug targets, diagnostic or toxicology assays,
and the Company's ability to successfully commercialize such tests.
Investors should consult Ciphergen's filings with the Securities
and Exchange Commission, including its Form 10-Q dated May 20,
2004, for further information regarding these and other risks of
the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker
Discovery Center and BioSepra are registered trademarks of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations of Ciphergen
Biosystems, Inc., +1-510-505 2297 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024